Ibrutinib, the first representative of BTK inhibitors, significantly improved the prognosis in high genetic risk chronic lymphocytic leukemia (CLL) resistant to traditional chemoimmunotherapy [1], in mantle cell lymphoma and in Waldenström’s macroglobulinemia as well. Here, BTK is linked to B-cell chronic lymphocytic leukemia.